[Congenital toxoplasmosis. Tolerability of the sulfadoxine-pyrimethamine combination. 24 cases].
The pyrimethamine-sulfadoxine combination, active against acute toxoplasmosis in the mouse, was administered to 24 children with congenital toxoplasmosis in doses of 500 mg sulfadoxine and 25 mg pyrimethamine per 20 kg bodyweight once every fortnight. The drug appeared to be as effective as other sulfonamide-pyrimethamine combinations. It was generally well tolerated and was withdrawn in only 3 patients on account of minor side-effects. Giving pyrimethamine-sulfadoxine together with folinic acid is a much simpler treatment of congenital toxoplasmosis than the usual ones.
D002675:Child, Preschool; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D011739:Pyrimethamine / Q000009:adverse effects / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000009:adverse effects / Q000627:therapeutic use*; D013424:Sulfanilamides / Q000627:therapeutic use*; D014125:Toxoplasmosis, Congenital / Q000097:blood / Q000188:drug therapy* / Q000276:immunology
D004338:Drug Combinations; D013424:Sulfanilamides; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002955:Leucovorin; D011739:Pyrimethamine
Toxoplasmose congénitale. Tolérance de l'association sulfadoxine-pyriméthamine. Vingt-quatre observations.